rituximab,ibrutinib
abbvie,biogen,roche,janssen
['cll', 'flair']
 professor peter hillmen from about the #eha22 abstract - phase 3 flair study, the results of the planned interim analysis in with cll. #oncotwitter 
Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.